These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 19284288)

  • 21. Predictors of sustained virologic response in hepatitis C genotype 4: beyond the usual suspects.
    Abdo AA; Sanai FM
    Ann Saudi Med; 2009; 29(1):1-3. PubMed ID: 19139625
    [No Abstract]   [Full Text] [Related]  

  • 22. Hepatitis C pharmacogenetics: state of the art in 2010.
    Afdhal NH; McHutchison JG; Zeuzem S; Mangia A; Pawlotsky JM; Murray JS; Shianna KV; Tanaka Y; Thomas DL; Booth DR; Goldstein DB;
    Hepatology; 2011 Jan; 53(1):336-45. PubMed ID: 21254181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Targeted against every genotype].
    Urban & Vogel
    MMW Fortschr Med; 2015 Apr; 157(6):34. PubMed ID: 26015198
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control.
    Larrubia JR; Moreno-Cubero E; Miquel J; Sanz-de-Villalobos E
    World J Gastroenterol; 2015 Mar; 21(12):3480-91. PubMed ID: 25834312
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacogenomic perspectives of chronic hepatitis C virus (HCV) infection.
    Tang J; Kaslow RA
    Pharmacogenomics J; 2004; 4(3):171-4. PubMed ID: 15069460
    [No Abstract]   [Full Text] [Related]  

  • 27. Impact of IL-28B SNPs on control of hepatitis C virus infection: a genome-wide association study.
    Imazeki F; Yokosuka O; Omata M
    Expert Rev Anti Infect Ther; 2010 May; 8(5):497-9. PubMed ID: 20455677
    [No Abstract]   [Full Text] [Related]  

  • 28. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic polymorphism of low-density lipoprotein receptor did not affect treatment outcome of chronic hepatitis C genotype 3.
    Tanwandee T; Pithukpakorn M; Vipatakul N; Charatcharoenwitthaya P; Chainuvati S; Nimanong S; Prachayakul V; Pongprasobchai S; Manatsathit S; Leelakusolvong S; Pausawasdi N; Kachintorn U; Limwongse C; Udompunturak S
    J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S147-53. PubMed ID: 21721440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Has genetics eradicated the good old predictors of hepatitis C treatment response?
    Pawlotsky JM
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):157-8. PubMed ID: 21492738
    [No Abstract]   [Full Text] [Related]  

  • 31. The interferon sensitivity determining region: all hepatitis C virus isolates are not the same.
    Herion D; Hoofnagle JH
    Hepatology; 1997 Mar; 25(3):769-71. PubMed ID: 9049233
    [No Abstract]   [Full Text] [Related]  

  • 32. SEN viruses and treatment response in chronic hepatitis C virus.
    Naoumov NV
    Lancet; 2002 May; 359(9319):1779-80; author reply 1780. PubMed ID: 12049896
    [No Abstract]   [Full Text] [Related]  

  • 33. The role of hepatitis C virus genotypes in development of autoimmune diseases.
    Sanver A; Gurlek A; Simsek H; Tatar G
    Diabetes Care; 2001 Jun; 24(6):1125-6. PubMed ID: 11375385
    [No Abstract]   [Full Text] [Related]  

  • 34. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan.
    Khaliq S; Raza SM
    Medicina (Kaunas); 2018 Nov; 54(5):. PubMed ID: 30400604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonresponse to treatment for hepatitis C: current management strategies.
    Yuan HJ; Lee WM
    Drugs; 2008; 68(1):27-42. PubMed ID: 18081371
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Aspects of the future of therapy for patients infected with a high viral load and interferon-resistant subtype of HCV.
    Matsumoto A; Kiyosawa K
    J Gastroenterol; 2002; 37(9):766-8. PubMed ID: 12375156
    [No Abstract]   [Full Text] [Related]  

  • 37. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 38. Current status of antiviral therapy for chronic hepatitis C.
    Lemon SM
    Adv Exp Med Biol; 1999; 458():29-37. PubMed ID: 10549377
    [No Abstract]   [Full Text] [Related]  

  • 39. Induction therapy with consensus interferon (CIFN) does not improve sustained virologic response in chronic hepatitis C.
    Layden TJ; Layden JE; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
    J Viral Hepat; 2002 Sep; 9(5):334-9. PubMed ID: 12225327
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HFE gene mutations prevent sustained virological response to interferon plus ribavirin in chronic hepatitis C patients with serum markers of iron overload.
    Coelho-Borges S; Cheinquer H; Cheinquer N; Krug L; Ashton-Prolla P
    Am J Gastroenterol; 2002 Jun; 97(6):1570-2. PubMed ID: 12094895
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.